PRECISION BIOLOGICS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2012-02-01
- Employees
- 11
- Market Cap
- -
Study of NEO-201 in Solid Tumors Expansion Cohorts
Phase 1
Recruiting
- Conditions
- Non Small Cell Lung CancerCervical CancerUterine CancerHead and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2018-03-26
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Precision Biologics, Inc
- Target Recruit Count
- 121
- Registration Number
- NCT03476681
- Locations
- 🇺🇸
INOVA Schar Cancer Institute, Fairfax, Virginia, United States
🇺🇸National Cancer Institute, Bethesda, Maryland, United States
QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer
Phase 1
Terminated
- Conditions
- Pancreatic Cancer, Adult
- Interventions
- First Posted Date
- 2013-04-17
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Precision Biologics, Inc
- Target Recruit Count
- 81
- Registration Number
- NCT01834235
- Locations
- 🇺🇸
Washington University in St. Louis, Saint Louis, Missouri, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beht Isreal Deaconess Medical Center, Boston, Massachusetts, United States
QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
Phase 1
Completed
- Conditions
- Metastatic Pancreatic CancerMetastatic Colorectal Cancer
- Interventions
- Drug: NPC-1C/NEO-102
- First Posted Date
- 2009-12-25
- Last Posted Date
- 2017-08-04
- Lead Sponsor
- Precision Biologics, Inc
- Target Recruit Count
- 94
- Registration Number
- NCT01040000
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
🇺🇸Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
© Copyright 2025. All Rights Reserved by MedPath